# Kwality Pharmaceuticals (NSE: KPL) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/KPL · Pivot · prices to 22 Oct 2026

Kwality Pharmaceuticals (NSE: KPL) closed at ₹3,531.50 on 22 Oct 2026, up 2.93% on the day. With a market capitalisation of ₹3,664 Cr, it ranks 899th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the FMCG sector; its industry is Drug Manufacturers - Specialty & Generic.

Its 52-week range is ₹1,561.00 (21 Apr 2026) to ₹3,949.00 (21 Sep 2026); the last close is 10.6% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹157 Cr (+35.8% year on year) and net profit ₹25 Cr (+74.8%), on a consolidated basis. Promoters held 54.86% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹3,531.50 |
| Market cap | ₹3,664 Cr |
| Debt to equity | 0.4 |
| 52-week high | ₹3,949.00 (21 Sep 2026) |
| 52-week low | ₹1,561.00 (21 Apr 2026) |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹157 Cr | +35.8% | ₹25 Cr | +74.8% | ₹24.39 |
| Q3 FY26 | ₹123 Cr | +46.2% | ₹16 Cr | +87.8% | ₹15.42 |
| Q2 FY26 | ₹111 Cr | +23.3% | ₹14 Cr | +66.9% | ₹13.60 |
| Q1 FY26 | ₹111 Cr | +39.2% | ₹12 Cr | +42.8% | ₹11.49 |
| Q4 FY25 | ₹116 Cr | +25.8% | ₹14 Cr | +241.5% | ₹13.95 |
| Q3 FY25 | ₹84 Cr | +8.1% | ₹9 Cr | +10.9% | ₹8.21 |
| Q2 FY25 | ₹90 Cr | +29.3% | ₹8 Cr | +36.0% | ₹8.15 |
| Q1 FY25 | ₹80 Cr | +18.7% | ₹8 Cr | +54.6% | ₹8.04 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY26 | ₹503 Cr | ₹67 Cr |
| FY25 | ₹370 Cr | ₹40 Cr |
| FY24 | ₹307 Cr | ₹24 Cr |
| FY23 | ₹251 Cr | ₹19 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 54.86%
- Foreign institutions: 3.13%
- Domestic institutions: 0.56%
- Non-institutions: 41.44%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Shree Renuka Sugars](https://app.pivotnow.in/stock/RENUKA) | ₹19.66 | ₹4,185 Cr | — | — |
| [Dalmia Bharat Sugar and Industries](https://app.pivotnow.in/stock/DALMIASUG) | ₹452.25 | ₹3,660 Cr | — | — |
| [Heritage Foods](https://app.pivotnow.in/stock/HERITGFOOD) | ₹366.70 | ₹3,403 Cr | 22.6 | — |
| [VST Industries](https://app.pivotnow.in/stock/VSTIND) | ₹200.16 | ₹3,400 Cr | — | — |
| [Parag Milk Foods](https://app.pivotnow.in/stock/PARAGMILK) | ₹260.85 | ₹3,277 Cr | 24.7 | — |
| [Gopal Snacks](https://app.pivotnow.in/stock/GOPAL) | ₹244.40 | ₹3,047 Cr | 41.4 | — |

## Questions and answers

### What is the share price of Kwality Pharmaceuticals today?

Kwality Pharmaceuticals (NSE: KPL) last closed at ₹3,531.50 on 22 Oct 2026. Its 52-week high is ₹3,949.00 and its 52-week low is ₹1,561.00.

### What is the market cap of Kwality Pharmaceuticals?

Kwality Pharmaceuticals' market capitalisation is ₹3,664 Cr (₹3,664 Cr) at the 22 Oct 2026 close, ranking 899th among the NSE companies Pivot tracks.

### Is Kwality Pharmaceuticals a debt-free company?

No. Kwality Pharmaceuticals' debt-to-equity ratio was 0.4 in FY26, with total debt of ₹131 Cr.

### What were Kwality Pharmaceuticals' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Kwality Pharmaceuticals reported revenue of ₹157 Cr, +35.8% year on year, and net profit of ₹25 Cr, +74.8% year on year.

### What is the shareholding pattern of Kwality Pharmaceuticals?

As of 30 Jun 2026: promoters 54.86%, foreign institutions 3.13%, domestic institutions 0.56%, non-institutions 41.44%.

### Who are Kwality Pharmaceuticals' competitors?

The listed FMCG companies closest to Kwality Pharmaceuticals by market cap are Shree Renuka Sugars, Dalmia Bharat Sugar and Industries, Heritage Foods, VST Industries, Parag Milk Foods and Gopal Snacks.

### Is Kwality Pharmaceuticals a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Kwality Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on KPL against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.